They suggested that recombinant Fibcd1 could serve as a therapeutic agent to prevent muscle loss in cancer cachexia or to aid its recovery, particularly as Fibcd1 interacts with receptors on muscle cells but not on cancer cells, indicating that its use is unlikely to promote cancer growth, making it a potentially safe therapeutic target. This evidence concerns the gene FIBCD1 and cancer.